S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Realm Therapeutics (RLM) Share Forecast, Price & News

GBX 11.50
0.00 (0.00%)
(As of 03/26/2019)
Today's Range
50-Day Range
52-Week Range
169,853 shs
Average Volume
800,861 shs
Market Capitalization
£13.40 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RLM News and Ratings via Email

Sign-up to receive the latest news and ratings for Realm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Realm Therapeutics

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc was founded in 2016 and is headquartered in Malvern, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
£501.92 thousand
Cash Flow
GBX 20.30 per share
Book Value
GBX 20.80 per share


Pretax Margin




Free Float
Market Cap
£13.40 million
Not Optionable


Overall MarketRank

1.08 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Realm Therapeutics (LON:RLM) Frequently Asked Questions

Who are Realm Therapeutics' key executives?
Realm Therapeutics' management team includes the following people:
  • Mr. John Alexander Martin, CEO & Exec. Director (Age 51)
  • Ms. Marella Thorell, CFO, COO, Company Sec. & Exec. Director (Age 52)
  • Dr. Christian Peters, Chief Medical Officer (Age 57)
What other stocks do shareholders of Realm Therapeutics own?
What is Realm Therapeutics' stock symbol?

Realm Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "RLM."

How do I buy shares of Realm Therapeutics?

Shares of RLM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Realm Therapeutics' stock price today?

One share of RLM stock can currently be purchased for approximately GBX 11.50.

How much money does Realm Therapeutics make?

Realm Therapeutics has a market capitalization of £13.40 million and generates £501.92 thousand in revenue each year.

What is Realm Therapeutics' official website?

The official website for Realm Therapeutics is www.realmtx.com.

How can I contact Realm Therapeutics?

Realm Therapeutics' mailing address is 508 Lapp Rd, MALVERN, PA 19355-1214, United States. The company can be reached via phone at +1-484-3212700.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.